Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

NCT05857085 on ClinicalTrials.gov · last registry update 2023-05-12

Finished 10 March 2022, after enrolling 90 people. Primary outcome, as filed: evaluation of endothelial function by flow mediated dilation (FMD) of brachial artery. semaglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: General and Teaching Hospital Celje
Sponsor type: Other
Enrollment: 90
Started: 2021-12-15
Primary completion: 2022-03-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

evaluation of endothelial function by flow mediated dilation (FMD) of brachial artery

Conditions studied

Endothelial Dysfunction · Diabetes Mellitus, Type 1 · Biomarkers · Endothelial Progenitor Cells · SGLT 2 Inhibitors · Incretins · Glucose Excursions · FMD · FPF · Arterial Stiffness

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.